| Hannah Linnea Kavookjian, MD | |
|
3901 Rainbow Blvd # Ms 3010, Kansas City, KS 66160-2004 | |
| (913) 574-9135 | |
| Not Available |
| Full Name | Hannah Linnea Kavookjian |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 8 Years |
| Location | 3901 Rainbow Blvd # Ms 3010, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184078487 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | D91180 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Kansas Hospital | Kansas city, KS | Hospital |
| Truman Medical Center Hospital Hill | Kansas city, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas University Physicians, Inc. | 8921911587 | 1456 |
| Truman Medical Center Incorporated | 7315841418 | 211 |
News Archive
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its PLacental eXpanded (PLX)-PAD cells for the treatment of intermittent claudication (IC), a peripheral artery disease (PAD). The double blind, randomized, placebo controlled trial enrolled 50 patients since October 2015 in the U.S., Germany, Israel, and South Korea.
Bayer Radiology & Interventional announced the introduction of the Certegra Workstation, an informatics-driven, touch‐screen hub that enables time savings and improved patient care through a powerful suite of CT Contrast Dose Management applications and a new P3T 2.0 operating environment.
"Timely identification and diagnosis of an autism spectrum disorder (ASD) can impact a child's development and is the key to opening the door to the services and therapies available to children with autism," says Paul Shattuck, Ph.D., assistant professor at the George Warren Brown School of Social Work at Washington University in St. Louis. "Unfortunately, our research shows that the average age of autism diagnosis is nearly six years old, which is three to four years after diagnosis is possible."
Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.
› Verified 8 days ago
| Entity Name | Kansas University Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its PLacental eXpanded (PLX)-PAD cells for the treatment of intermittent claudication (IC), a peripheral artery disease (PAD). The double blind, randomized, placebo controlled trial enrolled 50 patients since October 2015 in the U.S., Germany, Israel, and South Korea.
Bayer Radiology & Interventional announced the introduction of the Certegra Workstation, an informatics-driven, touch‐screen hub that enables time savings and improved patient care through a powerful suite of CT Contrast Dose Management applications and a new P3T 2.0 operating environment.
"Timely identification and diagnosis of an autism spectrum disorder (ASD) can impact a child's development and is the key to opening the door to the services and therapies available to children with autism," says Paul Shattuck, Ph.D., assistant professor at the George Warren Brown School of Social Work at Washington University in St. Louis. "Unfortunately, our research shows that the average age of autism diagnosis is nearly six years old, which is three to four years after diagnosis is possible."
Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hannah Linnea Kavookjian, MD 3901 Rainbow Blvd # Ms 3010, Kansas City, KS 66160-2004 Ph: (913) 574-9135 | Hannah Linnea Kavookjian, MD 3901 Rainbow Blvd # Ms 3010, Kansas City, KS 66160-2004 Ph: (913) 574-9135 |
News Archive
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its PLacental eXpanded (PLX)-PAD cells for the treatment of intermittent claudication (IC), a peripheral artery disease (PAD). The double blind, randomized, placebo controlled trial enrolled 50 patients since October 2015 in the U.S., Germany, Israel, and South Korea.
Bayer Radiology & Interventional announced the introduction of the Certegra Workstation, an informatics-driven, touch‐screen hub that enables time savings and improved patient care through a powerful suite of CT Contrast Dose Management applications and a new P3T 2.0 operating environment.
"Timely identification and diagnosis of an autism spectrum disorder (ASD) can impact a child's development and is the key to opening the door to the services and therapies available to children with autism," says Paul Shattuck, Ph.D., assistant professor at the George Warren Brown School of Social Work at Washington University in St. Louis. "Unfortunately, our research shows that the average age of autism diagnosis is nearly six years old, which is three to four years after diagnosis is possible."
Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.
› Verified 8 days ago
Dr. Terance T Tsue, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Ms 3010, Kansas City, KS 66160 Phone: 913-588-6701 Fax: 913-588-6708 | |
Frantzlee Lacrete, MD/MPH Otolaryngology Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-6739 | |
Christopher Jordan Boyd, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-6739 | |
Jennifer Villwock, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Mail Stop 3010, Kansas City, KS 66160 Phone: 913-588-8328 | |
Dr. Gregory Alan Ator, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Ms 3010, Kansas City, KS 66160 Phone: 913-588-6701 Fax: 913-588-6708 | |
Dr. Douglas A Girod, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Ms 3010, Kansas City, KS 66160 Phone: 913-588-6701 Fax: 913-588-6708 |